Myeloid neoplasms represent a highly heterogeneous group of diseases that encompass myeloproliferative, myelodysplastic (myeloproliferative/myelodysplastic) syndrome and acute myeloid leukemias. During recent years, considerable progress has been made in understanding disease pathogenesis, genetic landscapes of disease (driver mutations) and in development of diagnostic assays and novel therapies. In this presentation, we will share our experience with Oncomine Myeloid Research assay and the analytical validation of this assay. We will also discuss why targeted NGS method brings a unique advantage for detection of multiple variant alterations and fusions using a single platform.

Learning Objectives

1. Understand the benefits of next-generation sequencing in the profiling of haematological malignancies

2. Validation and user experience of combined DNA and RNA sequencing using Oncomine Myeloid Research Assay in haematological malignancies